These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21630282)

  • 1. Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach.
    Yoshii K; Hirayama M; Nakamura T; Toda R; Hasegawa J; Takei M; Mera Y; Kawabata Y
    J Pharm Sci; 2011 Nov; 100(11):4965-73. PubMed ID: 21630282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically-Based Pharmacokinetic and Pharmacodynamic Modeling for the Inhibition of Acetylcholinesterase by Acotiamide, A Novel Gastroprokinetic Agent for the Treatment of Functional Dyspepsia, in Rat Stomach.
    Yoshii K; Iikura M; Hirayama M; Toda R; Kawabata Y
    Pharm Res; 2016 Feb; 33(2):292-300. PubMed ID: 26350104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of acotiamide, an orally active acetylcholinesterase inhibitor, into the myenteric plexus of rat and dog stomachs.
    Yoshii K; Yamaguchi T; Hirayama M; Toda R; Kinomoto T; Kawabata Y; Chiba K
    Life Sci; 2016 Jan; 145():93-7. PubMed ID: 26682939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats.
    Kawachi M; Matsunaga Y; Tanaka T; Hori Y; Ito K; Nagahama K; Ozaki T; Inoue N; Toda R; Yoshii K; Hirayama M; Kawabata Y; Takei M
    Eur J Pharmacol; 2011 Sep; 666(1-3):218-25. PubMed ID: 21651906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the Uptake Transporter Responsible for Distribution of Acotiamide into Stomach Tissue.
    Hirayama M; Hoshino Y; Yoshii K; Toda R; Kawabata Y; Nakanishi T; Tamai I
    Mol Pharm; 2020 Apr; 17(4):1071-1078. PubMed ID: 32105080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acotiamide Hydrochloride, a Therapeutic Agent for Functional Dyspepsia, Enhances Acetylcholine-induced Contraction via Inhibition of Acetylcholinesterase Activity in Circular Muscle Strips of Guinea Pig Stomach.
    Ito K; Kawachi M; Matsunaga Y; Hori Y; Ozaki T; Nagahama K; Hirayama M; Kawabata Y; Shiraishi Y; Takei M; Tanaka T
    Drug Res (Stuttg); 2016 Apr; 66(4):196-202. PubMed ID: 26418413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia.
    Tack J; Janssen P
    Expert Opin Investig Drugs; 2011 May; 20(5):701-12. PubMed ID: 21417958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia.
    Suzuki H; Hibi T
    Neurogastroenterol Motil; 2010 Jun; 22(6):595-9. PubMed ID: 20553562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging treatments in neurogastroenterology: Acotiamade, a novel treatment option for functional dyspepsia.
    Matsushita M; Masaoka T; Suzuki H
    Neurogastroenterol Motil; 2016 May; 28(5):631-8. PubMed ID: 26730749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography.
    Kusunoki H; Haruma K; Manabe N; Imamura H; Kamada T; Shiotani A; Hata J; Sugioka H; Saito Y; Kato H; Tack J
    Neurogastroenterol Motil; 2012 Jun; 24(6):540-5, e250-1. PubMed ID: 22385472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride.
    Matsunaga Y; Tanaka T; Yoshinaga K; Ueki S; Hori Y; Eta R; Kawabata Y; Yoshii K; Yoshida K; Matsumura T; Furuta S; Takei M; Tack J; Itoh Z
    J Pharmacol Exp Ther; 2011 Mar; 336(3):791-800. PubMed ID: 21123674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acotiamide: first global approval.
    Nowlan ML; Scott LJ
    Drugs; 2013 Aug; 73(12):1377-83. PubMed ID: 23881665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to an acotiamide therapeutic regimen improves long-term outcomes in patients with functional dyspepsia.
    Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Miura Y; Lefor AK; Yamamoto H
    J Gastrointestin Liver Dis; 2017 Dec; 26(4):345-350. PubMed ID: 29253047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome.
    Altan E; Masaoka T; Farré R; Tack J
    Expert Rev Gastroenterol Hepatol; 2012 Sep; 6(5):533-44. PubMed ID: 23061703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia.
    Nakamura K; Tomita T; Oshima T; Asano H; Yamasaki T; Okugawa T; Kondo T; Kono T; Tozawa K; Ohda Y; Fukui H; Kazuhito F; Hirota S; Watari J; Miwa H
    J Gastroenterol; 2017 May; 52(5):602-610. PubMed ID: 27639387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of acotiamide on functional dyspepsia patients with heartburn who failed proton pump inhibitor treatment in Japanese patients: A randomized, double-blind, placebo-controlled crossover study.
    Funaki Y; Ogasawara N; Kawamura Y; Yoshimine T; Tamura Y; Izawa S; Ebi M; Sasaki M; Kasugai K
    Neurogastroenterol Motil; 2020 Feb; 32(2):e13749. PubMed ID: 31612597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acotiamide improves stress-induced impaired gastric accommodation.
    Ikeo K; Oshima T; Sei H; Kondo T; Fukui H; Watari J; Miwa H
    Neurogastroenterol Motil; 2017 Apr; 29(4):. PubMed ID: 27860042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial.
    Tack J; Pokrotnieks J; Urbonas G; Banciu C; Yakusevich V; Bunganic I; Törnblom H; Kleban Y; Eavis P; Tsuchikawa M; Miyagawa T
    Neurogastroenterol Motil; 2018 Jun; 30(6):e13284. PubMed ID: 29315999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia.
    Tack J; Masclee A; Heading R; Berstad A; Piessevaux H; Popiela T; Vandenberghe A; Kato H
    Neurogastroenterol Motil; 2009 Mar; 21(3):272-80. PubMed ID: 19254354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage.
    Matsueda K; Hongo M; Tack J; Aoki H; Saito Y; Kato H
    Neurogastroenterol Motil; 2010 Jun; 22(6):618-e173. PubMed ID: 20059698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.